Imunon, Inc.

Imunon, Inc. is a clinical-stage biotechnology company developing non-viral DNA-based therapies and vaccines. Its lead platform, TheraPlas®, is being advanced for solid tumors such as advanced ovarian cancer, while PlaCCine® is designed for vaccine applications in infectious diseases.

2.32

2.32

— Imunon, Inc.
%
Oncology therapeutics70% Includes IMNN-001 and related development work for solid tumors, especially advanced ovarian cancer.
Vaccine platform15% Includes PlaCCine® programs that code viral antigens for infectious disease vaccines.
Clinical development and regulatory10% Includes preclinical, clinical, FDA interaction, and trial advancement activities.
Manufacturing and CMC5% Includes process development, potency assay work, and cGMP manufacturing readiness.

Imunon does not yet commercialize products, so its near-term 'customers' are primarily clinical trial sites,...

  • Regulators and clinical trial stakeholdersprimary

    The company works with the FDA, trial investigators, and manufacturing reviewers to advance IMNN-001 through development and align on CMC requirements.

  • Future biopharma collaboration partnersprimary

    Potential partners may fund, run, or commercialize programs in exchange for rights or shared economics.

  • Oncology treatment providerssecondary

    If approved, hospitals and oncology specialists would use IMNN-001 for advanced ovarian cancer patients.

  • Vaccine development partnersemerging

    PlaCCine® could be licensed or partnered for infectious disease vaccine development and commercialization.

Imunon is headquartered in the United States and its disclosed operating footprint centers on U.S...

  • •United States is the core operating and regulatory market
  • •Huntsville, Alabama hosts IMNN-001 clinical-scale manufacturing
  • •FDA meetings and approvals are central to program progress
  • •No meaningful commercial geography yet because products are not sold
  • •Future partnerships could expand geographic reach outside the U.S.

Imunon’s strategy is to advance IMNN-001 into a Phase 3 pivotal study, secure FDA alignment on clinical and CMC...

01
Advance IMNN-001 into Phase 3short-term

Clinical proof-of-concept and pivotal data are the main value drivers for a pre-revenue biotech.

02
Secure financing and non-dilutive supportshort-term

The company has limited cash and substantial going-concern risk, so funding determines operating continuity.

03
Build partnership optionalitymedium-term

Collaborations can reduce capital needs and accelerate development or commercialization.

Imunon is a pre-revenue clinical-stage biotech, so its main risks are clinical failure, regulatory delay, and financing...

critical

Going-concern and liquidity shortfall

The company disclosed substantial doubt about its ability to continue without additional capital.

Scope
Cash runway and ability to fund trials
Materiality
high
high

Clinical development failure

Drug research and development is inherently uncertain and pivotal studies can fail at any stage.

Scope
IMNN-001 and future pipeline programs
Materiality
high
high

Financing dilution and unfavorable terms

The company relies on equity, partnerships, and grants, which may be unavailable or dilutive.

Scope
ATM program and future capital raises
Materiality
high
high

Regulatory and CMC execution risk

FDA alignment on manufacturing, potency assays, and comparability is required for Phase 3 and BLA readiness.

Scope
IMNN-001 manufacturing and approval path
Materiality
high
medium

Nasdaq listing compliance

Failure to meet continued listing standards could lead to delisting and reduced liquidity.

Scope
Common stock trading on Nasdaq
Materiality
medium
Going-concern assessment
May require additional disclosures and highlights liquidity risk
Equity issuance and dilution
Increases dilution and can pressure valuation
Collaboration and licensing accounting
Could shift reported revenue and deferred income
Grant and subsidy recognition
Could reduce net loss in periods received

Immunovant, Inc.

IMVT · Biological Products, (No Diagnostic Substances)

AIM ImmunoTech Inc.

AIM · Biological Products, (No Diagnostic Substances)

IMMUCELL CORP /DE/

ICCC · In Vitro & In Vivo Diagnostic Substances

IMMUNIC, INC.

IMUX · Pharmaceutical Preparations

Immunome Inc.

IMNM · Pharmaceutical Preparations

Immunocore Holdings plc

IMCR · Biological Products, (No Diagnostic Substances)

: 28.4.2026